On July 30, 2025, Judge Brian R. Martinotti of the United States District Court of the District of New Jersey granted a motion to dismiss a putative securities fraud class action against a drug manufacturing company (the “Company”) and its CEO and CFO (the “Individual Defendants” and, together, the “Defendants”) for alleged violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Feldman v. Scynexis, Inc. , No. 2:23-cv-22082 (BRM) (CLW) (D.N.J. July 30, 2025). Plaintiff alleged that Defendants made material misstatements and omissions regarding the Company’s drug manufacturing process and compliance with applicable regulatory standards, but the Court found no actionable misstatement or omission and dismissed the complaint without

See Full Page